| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 33.43 | 4.7% | 11.9% |
| Total Income | 33.43 | 4.7% | 11.9% |
| Expenditure | 55.96 | 9.5% | 10.2% |
| PBT | -67.02 | 199.3% | 80.1% |
| Net Profit | -67.02 | 199.3% | 79.9% |
| OPM | -67.38% | 8.93pp | 3.08pp |
| NPM | — | ||
| EPS | -2.32 | 127.5% | 46.3% |
Karyopharm Reports Q2 2026 Financial Results and Highlights Progress Toward Myelofibrosis sNDA Submission
13 Aug 2026 · 13 Aug, 5:12 pm
Summary
Karyopharm Therapeutics reported second quarter 2026 total revenue of $33.4 million, down from $37.9 million in the prior year, primarily due to a decrease in license and other revenue. However, U.S. XPOVIO net product revenue saw a slight increase to $30.8 million from $29.7 million year-over-year. The company is on track to submit its sNDA for selinexor in myelofibrosis in August and reaffirmed its full-year 2026 total revenue guidance. Despite a wider net loss of $67.0 million in Q2 2026 compared to $37.3 million in Q2 2025, management highlighted progress in its myelofibrosis program and constructive engagement with the FDA.
Key Highlights
- 1
Total revenue for the second quarter of 2026 was $33.4 million, a decrease from $37.9 million in the second quarter of 2025.
- 2
U.S. XPOVIO net product revenue was $30.8 million for the second quarter of 2026, an increase from $29.7 million in the second quarter of 2025.
- 3
Royalty revenue increased to $2.5 million in the second quarter of 2026 compared to $1.6 million in the second quarter of 2025.
- 4
The company remains on track to submit its planned supplemental New Drug Application (sNDA) in August under the Accelerated Approval pathway for selinexor in combination with ruxolitinib for patients with myelofibrosis.
- 5
Net loss for the second quarter of 2026 was $67.0 million, or $2.32 per basic and diluted share, compared to a net loss of $37.3 million, or $4.32 per basic and diluted share, for the second quarter of 2025.
- 6
The company reaffirms its full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million.
Management Comments
Richard Paulson
Our planned submission under the Accelerated Approval pathway represents the beginning of an important new chapter for Karyopharm and an important milestone for the myelofibrosis community. If approved, selinexor plus ruxolitinib would become the first approved combination therapy for patients with myelofibrosis, introducing a novel therapeutic mechanism for the treatment of this disease within the multi-billion-dollar U.S. marketplace. Our planned submission follows productive engagements with the FDA and reflects the speed, focus, urgency and extraordinary commitment of our teams. We look forward to continuing to work closely with the FDA. Together with the continued scientific engagement we are seeing across the myelofibrosis community, we believe the strength and consistency of the SENTRY data reinforce the potential of selinexor to fundamentally change the treatment of patients with myelofibrosis.
Informational and educational content only. Not investment advice.